Sachs David C. 4
4 · ImmunityBio, Inc. · Filed Jan 3, 2025
Insider Transaction Report
Form 4
Sachs David C.
Chief Financial Officer
Transactions
- Tax Payment
Common Stock
2024-12-31$2.56/sh−15,405$39,437→ 200,830 total - Exercise/Conversion
Restricted Stock Units
2024-12-31−30,397→ 75,999 total→ Common Stock (30,397 underlying) - Exercise/Conversion
Common Stock
2024-12-31+30,397→ 216,235 total
Footnotes (2)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
- [F2]17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.